Drug intelligence / Profile preview

VTX-1218

Development stage: Preclinical
Lead developer: Verseau Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

VTX-1218 is a humanized IgG1 monoclonal antibody that targets VSIG4 (V-set and immunoglobulin domain containing 4), a type-I receptor from the B7-like family highly expressed on tumor-associated macrophages and dendritic cells in most tumor types. By binding to VSIG4, VTX-1218 repolarizes macrophages to a pro-inflammatory state, activates T-cells, and attracts other immune cells, generating a coordinated antitumor immune response. The drug is being developed by Verseau Therapeutics for the treatment of solid tumors and is currently in preclinical development[1][2][3][5][6].

Targets

VSIG4 (V-set and immunoglobulin domain-containing protein 4)

Beyond the preview

Go deeper on VTX-1218.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VTX-1218.

Explore the full profile